Amgen (AMGN) continues to unsettle the bio-tech investment landscape with a series of noticeable and dynamic moves. The company has recently acquired
landmark results from a trial of its highly anticipated drug,
Repatha. Additionally, they have acquired
new other approved indications, thus contributing to their possible increased valuation. Position shifts in Amgen Inc’s stock have occurred among several investment institutions, with a notable stake growth by the
AMF Tjanstepension AB and
Corundum Group Inc. Other investors remained cautious, as indicated by Bank of America Securities and Citi maintaining their ‘Sell’ and ‘Hold’ ratings correspondingly. Amgen demonstrated a significant investment in its operations with an announcement of a
$650M expansion of its facility in Puerto Rico, aiming to bolster its manufacturing output and creating approximately
750 new jobs. The Progressive success of Repatha’s trial coupled with promising expansion announcements has pushed the company’s shares up by
9.7%. Investors are now diving into Amgen, eyeing the company's
strong therapies pipeline as one of the key reasons behind their bullish outlook. They have also unveiled
top-line results from their ASCEND study of Rocatinlib. However, it should be noted that some shareholders, including Sen. Sheldon Whitehouse and Franklin Street Advisors Inc., have recently sold their Amgen shares, referring back to some market uncertainties.
Amgen AMGN News Analytics from Tue, 24 Jun 2025 07:00:00 GMT to Sat, 04 Oct 2025 21:17:53 GMT -
Rating 5
- Innovation 6
- Information 7
- Rumor -3
